Fiserv Explores Sale of STAR Payments Network as Major U.S. Banks Show Interest 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
LG Energy Solution Q2 Profit Plunges 77% Despite Revenue Growth on Weak EV Demand 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
CAMBRIDGE, Mass., May 08, 2018 -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Evelo has granted the underwriters a 30-day option to purchase up to an additional 796,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. Evelo’s common stock is expected to begin trading on The Nasdaq Global Select Market on May 9, 2018 under the ticker symbol “EVLO.” All of the common stock is being offered by Evelo. The gross proceeds of the offering are expected to be $85 million, excluding any exercise of the underwriters’ option.
Morgan Stanley, Cowen and BMO Capital Markets are acting as book-running managers for the offering. JMP Securities is acting as lead manager for the offering.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at (631) 274-2806; or BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, Attn: Equity Syndicate Department, by telephone at 800-414-3627, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Contact
Evelo Biosciences
Stefan Riley
617-704-2333
[email protected]
